Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference

Lausanne, Switzerland (ots/PRNewswire) -

Debiopharm presents preclinical results for 2 anti-cancer targeted
therapies Debio 1143 and Debio 1347

Debiopharm International SA (Debiopharm), part of Debiopharm
Group(TM), a Swiss-based global biopharmaceutical company developing
prescription drugs that target unmet medical needs as well as
companion diagnostics, today announced that preclinical data on the
investigational compounds Debio 1143 (SMAC mimetic) and Debio
1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015
Annual meeting of the American Association for Cancer Research (AACR)
taking place in Philadelphia.

"Oncology has and will continue to benefit from combined and
targeted therapies. Results from these preclinical studies underscore
the potential clinical value of our two anti-cancer targeted
therapies" said Dr Nigel McCracken, Vice President, Translational
Medicine. "Currently both Debio 1143 and Debio 1347 are in Clinical
Development and Debiopharm remains committed to exploring new
combinations and new indications to provide improved benefit to
patients suffering from cancers".

AACR 2015 Abstract

Compound Title Date and Time No.
Debio 1143 SMAC mimetic and radiotherapy synergize to Sun, Apr 19, #283
enhance antitumor immunity in lung cancer by 1:00 - 5:00 pm
targeting immunosuppressive cells

Debio 1143 synergizes with taxanes, Mon, Apr 20, #2529
topoisomerase and bromodomain inhibitors to 1:00 - 5:00 pm
inhibit growth of lung adenocarcinoma

The IAP inhibitor Debio 1143 reverses Mon, Apr 20, #2700
carboplatin resistance in ovarian cancer cells 1:00 - 5:00 pm
by inducing both apoptosis and necroptosis

Debio 1347 Characterization of two novel oncogenic Sun, Apr 19, #689
FGFR2 fusions sensitive to the FGFR-selective 1:00 - 5:00 pm
inhibitor Debio 1347 in cholangiocarcinoma

Formulation switch and pharmacokinetics/ Mon, April 20, Abstract
pharmacodynamics of Debio 1347 (CH5183284), a 8:00 - 12:00 am CT228
novel FGFR inhibitor, in a first-in-human dose
escalation trial in solid tumors patients

Additional poster regarding Debio 1347 to be Sun, Apr 19, Abstract
presented by Chugai Pharmaceutical, the 1:00 - 5:00 pm #123
originator of the compound: Mechanism of
oncogenic signal activation by the novel
fusion kinase FGFR3-BAIAP2L1

About Debiopharm International SA

Debiopharm Group(TM) is a Swiss-based global biopharmaceutical
group of four companies active in drug development, GMP manufacturing
of proprietary drugs, diagnostics, and investments. Debiopharm
International SA is focused on the development of prescription drugs
that target unmet medical needs. The company in-licenses, develops
and/or co-develops promising biological and small molecule drug
candidates for global registration. The products are commercialized
through out-licensing to pharmaceutical partners to give access to
the largest number of patients worldwide.

For more information, please visit: http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel: +41(0)21-321-01-11

Additional Media Contacts
In London
Maitland
Martin Barrow
mbarrow@maitland.co.uk
Tel: +44(0)20-7395-0444

In New York
Russo Partners, LLC
Marissa Goberdhan
Account Executive
marissa.goberdhan@russopartnersllc.com
Tel: +1-212-845-4253

ots Originaltext: Debiopharm Group
Im Internet recherchierbar: http://www.presseportal.de